Recently, glucagon-like peptide 1 (GLP-1) agonists have garnered interest for IIH management due to their weight reduction and potential CSF production-decreasing effects
Weight loss results are the most frequently mentioned positive outcome, with users reporting losses ranging from 14 to 40 pounds depending on the treatment and duration
Migraines are severe headaches often accompanied by vomiting, pain, nausea and extreme sensitivity to light and sound
: - 4.1% of GLP-1 users received an osteoporosis diagnosis, compared with 3.2% of nonusersabout a 29% higher risk
Drucker DJ: Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
MARNYS L-Carnitin 2000 enthlt L-Carnitin-Tartrat, das 66% des L-Carnitins liefert, das durch das Drug Master File (DMF) zertifiziert ist und hchste Qualitts- und Sicherheitsstandards sowie die Stabilitt und Reinheit des Rohstoffs garantiert